IDG
The Illuminating the Druggable Genome (IDG) Program is an NIH-sponsored initiative to study the properties and functions of dark proteins within the known families of drug targets. During the IDG pilot phase the program developed a website, called Pharos, that integrates information about dark proteins so that researchers everywhere can easily access it, catalyzing their own research and helping them find new proteins that may be of interest. In addition, IDG supported several technology development projects to enable the study of dark proteins in a high throughput manner. During the Implementation Phase, IDG established a large network of collaborators to expand the informatics tools developed in the Pilot Phase, elucidate the function of understudied proteins from three key druggable protein families (GPCRs, ion channels, and kinases), and disseminate the IDG-generated resources to the greater scientific community.
Table: Classification of the 134 IDG dark kinases by substrate. Listed alphabetically within each category. Protein kinases: putative serine, threonine, and tyrosine kinases. Pseudokinases: same fold as the protein kinases, but lack one or more canonical catalytic site residues. Other kinases: includes inositol, glycerol, nucleotide, and thiamine kinases. Regulatory proteins: phosphotransferase activity not established; modulate other kinases.
SGC-UNC is contributing to the Drug and Resource Generation Center for Kinases led by Gary Johnson. We will identify cell active inhibitors for the dark kinases on the IDG list. Many of these kinase inhibitors will fill gaps in our public chemogenomic set KCGS. IDG data and resources are available at the Dark Kinase Knowledgebase.
IDG Workflow:
